Last reviewed · How we verify
Parestat(generic parecoxib)
Parecoxib is a selective COX-2 inhibitor that reduces prostaglandin production to provide anti-inflammatory and analgesic effects.
Parecoxib is a selective COX-2 inhibitor that reduces prostaglandin production to provide anti-inflammatory and analgesic effects. Used for Acute postoperative pain, Perioperative pain management.
At a glance
| Generic name | Parestat(generic parecoxib) |
|---|---|
| Sponsor | University of Malaya |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Parecoxib selectively inhibits cyclooxygenase-2 (COX-2), an enzyme responsible for producing pro-inflammatory prostaglandins. By blocking COX-2 while sparing COX-1, it provides pain relief and reduces inflammation with potentially fewer gastrointestinal side effects compared to non-selective NSAIDs. It is administered intravenously or intramuscularly, making it suitable for acute postoperative pain management.
Approved indications
- Acute postoperative pain management
- Perioperative pain relief
Common side effects
- Nausea
- Vomiting
- Dizziness
- Headache
- Injection site reactions
Key clinical trials
- Study Comparing Dynastat and Parestat Pain Relief Medications for Patients After Breast Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Parestat(generic parecoxib) CI brief — competitive landscape report
- Parestat(generic parecoxib) updates RSS · CI watch RSS
- University of Malaya portfolio CI